References
- Taylor R. L., Maurer J. L., Tinklenberg J. R. Management of “bad trips” in an evolving drug scene. JAMA 1970; 213: 422
- Gossett J. T., Lewis J. M., Phillips V. A. Extent and prevalance of illicit drug use as reported by 56,745 students. JAMA 1971; 216: 1464
- Snyder S. H., Faillace L. A., Hollister L. E. 2,5-dimethoxy-4-methyl amphetamine (STP): a new hallucinogenic drug. Science 1967; 158: 669
- Shulgin A. T., Bunnell A. T., Sargent T. The psycholto-mimetic properties of 3,4,5-trimethoxy-amphetomine. Nature (London) 1961; 189: 1011
- Shulgin A. T. 3-Methoxy-4,5-methylenedioxyamphetamine, a new psychotomimetic agent. Nature (London) 1964; 201: 1120
- Read J., University of Alberta Hospital. personal communication
- Rappolt R. T., Sr. personal communication
- Louria D. B. Some aspects of the current drug scene, with emphasis on drugs in use by adolescents. Pediatrics 1968; 42: 904
- Mannich C., Jacobsohn W. Hydroxyphenalkylamines and dihydroxyphenalkylamines. Berichte 1910; 43: 189
- Ide W. S., Buck J. S. 3-Methyl-3,4-dihydroisoquinolines and 3-methyl-1,2,3,4-tetrahydroisoquinolines. J. Am. Chem. Soc 1940; 62: 425
- Elks J., Hey D. C. β-3,4-Methylenedioxyisopropylamine. J. Chem. Soc 1943; 15
- Hey D. H., Williams J. M. 1-Pyridylisoquinolines. J. Chem. Soc 1951; 1527
- Gunn J. A., Guxd M. R., Sachs L. The action of some amines related to adrenaline: methoxyphenylisopropylamines. J. Physiol. London 1939; 95: 485
- Fellows E. J., Cook L. U.S. Patent. 2, 1961, 974 148 MDA as anorexigenic
- British Patent. 82880, 1960, Smith Kline and French Laboratories, MDA as ataractic
- Brown H. D. U.S. Patent. 2, 1958, 820 739 MDA as antitussive
- Mann P. J. G., Quastel J. H. Benzedrine (β-phenyliso-propylamine) and brain metabolism. Biochem. J. 1940; 34: 414
- Fellows E. J., Bernhein F. Effect of a number of aryl-alkylamines on the oxidation of tyramine by amine oxidase. J. Pharmacol. Exptl. The rap. 1950; 100: 94
- Ota J. Inhibition of amine oxidase by benzedrine derivatives. Bull. Chem. Soc. Japan 1948; 21: 75
- Fujimura H., Ohata K. Effects of several analeptics on brain amine oxidase activity and respiration. Nippon Yakurigaku Zacchi 1958; 54: 416
- Goldstein M., Contrera J. F. Inhibition of 3,4-dihydroxy-phenylethylamine (dopamine) β-oxidase in vitro. Experientia 1961; 17: 267
- Leffler E. B., Spencer H. M., Burger A. Dissociation constants of adrenergic amines. J. Am. Chem. Soc 1951; 73: 2611
- Ogawa M. Combined use of drugs m: The combined effects of chlorpromazine and its derivatives on the action of analgesics. Nippon Yakurigaku Zacchi 1958; 54: 416
- Daly J. W., Creveling C. R., Witkop B. The chemorelease of norepinephrine from mouse hearts: Structure activity relations: 1-sympathomimetics and related agents. J. Med. Chem. 1966; 9: 273
- Van der Schoot J. B., Ariens E. J., Von Rossum J. M.J. A. Th., Hurkmans M. Phenylisopropylamine derivatives, structure and actions. Arzneimittel Forsch. 1962; 12: 902
- Fairchild M. D., Alles G. A., Jenden D. J., Mickey M. R. The effects of mescaline, amphetamine and four-ring substituted amphetamine derivatives on spontaneous brain electrical activity in cats. Intern. J. Neuropharmacol. 1967; 6: 151
- Benington F., Morin R. D., Clark C. C., Jr., Fox R. P. Psychopharmacological activity of ring- and side chain-substituted 0-phenethylamines. J. Org. Chem. 1958; 23: 1979
- Alles G. A. Some Relations between Chemical Structive and Physiological Action of Mescaline and Related Compounds. Neuropharmacology, H. A. Abramson. Josiah Macey Jr. Foundation, New York 1959
- Naranjo C., Shulgin A. T., Sargent T. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Med. Pharmacol. Exptl. 1967; 17: 359
- Loman J., Myerson P. G., Myerson A. Experimental pharmacology of postencephalitic Parkinson's disease. Trans. Am. Neurol. Assoc 1941; 67: 201
- Scaggs P. personal communication